Top in allergy/asthma: EURneffy closer to approval; caregivers seek allergy info online
Click Here to Manage Email Alerts
The European Medicines Agency Committee for Medicinal Products for Human Use has recommended marketing authorization of ARS Pharmaceuticals’ EURneffy epinephrine nasal spray in the European Union, according to a press release.
“Today’s announcement marks a major milestone in the treatment of severe allergies and moves us one step closer to bringing EURneffy to patients in the EU as the first and only needle-free adrenaline option for the emergency treatment of allergic reactions, up to anaphylaxis,” Richard Lowenthal, cofounder, president and CEO of ARS Pharmaceuticals, said in the press release.
ARS Pharmaceuticals expects marketing authorization in the third quarter of 2024, with full European availability in the fourth quarter. In the United States, its neffy brand has been given an Oct. 2 action date from the FDA. It was the top story in allergy/asthma last week.
In another top story, researchers found that nearly two out of three caregivers of children with a food allergy use online searches weekly to find information on food allergies.
Read these and more top stories in allergy/asthma below:
Epinephrine nasal spray recommended for approval in European Union
An epinephrine nasal spray is closer to approval in Europe, according to a press release from ARS Pharmaceuticals. The European Commission has adopted a positive opinion and recommended marketing authorization for EURneffy use in emergency care. Read more.
Most caregivers of children with food allergies go online at least weekly for information
More patients are using online platforms to obtain information on food allergies, trusting professional organizations and allergists the most, according to a study published in Annals of Allergy and Asthma and Immunology. Read more.
Children achieve remission in eosinophilic esophagitis with dupilumab
There were significant differences in percentages of children with eosinophilic esophagitis who experienced histologic remission with dupilumab (Dupixent; Sanofi, Regeneron) compared with placebo, according to a study published in The New England Journal of Medicine. Read more.
Q&A: Testing for polyethylene glycol in drug allergies remains challenging
Hypersensitivity to polyethylene glycol may be rare, but when reactions to PEG in drugs do occur, they often are due to molecular weights of 3350 and higher, according to a study published in Annals of Allergy, Asthma & Immunology. Read more.
APA-AAI president-elect talks upcoming conference, advancements in treatment
The Association of PAs in Allergy, Asthma & Immunology will be holding its 16th annual conference from Aug. 2 to 4 in San Antonio. APA-AAI president-elect Heather O’Connell, PA-C spoke with Healio about the goals of the conference and topics to be addressed, including drug allergy, anaphylaxis, ENT patients and conditions, periodic fever syndromes, and more. Read more.